Kyverna Therapeutics (KYTX) Other Accumulated Expenses (2023 - 2026)

Kyverna Therapeutics' Other Accumulated Expenses history runs 4 years deep, the most recent figure standing at $3.0 million for Q1 2026.

• Quarterly Other Accumulated Expenses rose 71.94% year-over-year to $3.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.0 million (up 71.94% YoY) and the FY2025 annual result came in at $2.2 million, down 25.22% from the prior year.
• Other Accumulated Expenses was $3.0 million for Q1 2026 at Kyverna Therapeutics, up from $2.2 million in the prior quarter.
• Across five years, Other Accumulated Expenses topped out at $3.0 million in Q1 2026 and bottomed at $1.2 million in Q2 2025.
• A 4-year average of $2.1 million and a median of $2.0 million in 2025 frame the typical range for Other Accumulated Expenses.
• Annual changes were most pronounced in 2025 — Other Accumulated Expenses dropped 25.22% — and 2026, when it jumped 71.94%.
• Kyverna Therapeutics' Other Accumulated Expenses stood at $1.8 million in 2023, then surged by 62.27% to $2.9 million in 2024, then fell by 25.22% to $2.2 million in 2025, then surged by 39.15% to $3.0 million in 2026.
• Business Quant data shows KYTX's Other Accumulated Expenses at $3.0 million in Q1 2026, $2.2 million in Q4 2025, and $2.0 million in Q3 2025.